Share this video  

ESMO 2018 | Unmet clinical needs for platinum-resistant ovarian cancer patients

Lurbinectedin, a novel agent, failed to exhibit superiority over standard chemotherapy treatment in the Phase III CORAIL trial (NCT02421588). Domenica Lorusso, MD, PhD, of the IRCCS National Cancer Institute, Milan, Italy, discusses the implications of this result at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.